GMA
The authors studied Ganoderma lucidum polysaccharides in mouse models of ageing. Treatment enriched Blautia coccoides, increased faecal butyrate and reduced barrier damage, systemic inflammation and microglial activation signals.
The causal chain was explored through faecal microbiota transfer, direct B. coccoides or butyrate supplementation and NLRP3-deficient animals. This makes the rationale more informative than a simple association between microbiota composition and behaviour.
It remains preclinical work. Human translation requires extract characterisation, bioavailability, dose, safety and trials measuring clinically relevant outcomes.
The study offers an articulated rationale for brain-health and healthy-ageing ingredients built around microbiota, metabolites and inflammation.
A preclinical study in mice and cells. It does not establish human cognitive efficacy, useful dose or safety and cannot be extended to every reishi extract.
Editorial note. This content is intended for industry professionals. It does not constitute medical advice, therapeutic guidance or regulatory advice. Read our editorial method.
Read the original source · npj Parkinson’s Disease ↗